NCT06012708View on ClinicalTrials.gov

Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 11, 2023

Primary Completion Date

November 5, 2024

Study Completion Date

December 16, 2024

Conditions
Advanced Solid Tumors
Interventions
DRUG

KN510 60mg/day + KN713 60mg/day

Once daily with 28 days (4 weeks) as one cycle.

DRUG

KN510 120mg/day + KN713 60mg/day

Once daily with 28 days (4 weeks) as one cycle.

DRUG

KN510 120mg/day + KN713 90mg/day

Once daily with 28 days (4 weeks) as one cycle.

DRUG

KN510 120mg/day + KN713 120mg/day

Once daily with 28 days (4 weeks) as one cycle.

Trial Locations (1)

Unknown

National Cancer Center, Goyang-si

All Listed Sponsors
lead

New Cancer Cure-Bio Co.,Ltd.

INDUSTRY

NCT06012708 - Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713 | Biotech Hunter | Biotech Hunter